Takeda Pharmaceutical's LEUPLIN Now Applicable to Adjunctive Treatment of Premenopausal Breast Cancer.Tokyo, Japan, Aug 22, 2005 - (JCNN JCNN Japan Corporate News Network ) - Takeda Pharmaceutical announced on August 19 that the Ministry of Health, Labor and Welfare has approved an additional indication for LEUPLIN SR For Injection Kit 11.25, the company's proprietary agent indicated for the treatment of prostate cancer or endometriosis endometriosis (ĕn'dəmē'trē-ō`sĭs), a condition in which small pieces of the endometrium (the lining of the uterus) migrate to other places in the pelvic area. , as of August 18. With this approval, LEUPLIN, including LEUPLIN Injection 3.75 and LEUPLIN Injection Kit 3.75, is now applicable to the adjunctive treatment, namely preventing relapses, of premenopausal pre·me·no·paus·al adj. Of or relating to the years or the stage of life immediately before the onset of menopause. premenopausal adjective breast cancer. As a sustained-release formulation, LEUPLIN SR exerts effects when it is taken only once every 12 weeks. In Japan, over 10,000 people died of breast cancer in 2004, accounting for 8.4% of the nations total number of deaths by cancer. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion